Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | ADH1B | P00325 | 2/20 | 0.44 |
| ▸ | ADH1C | P00326 | 2/20 | 0.44 |
| ▸ | ADH1A | P07327 | 2/20 | 0.44 |
| ▸ | ADH7 | P40394 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | ADH4 | P08319 | 1/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.41 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.41 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22771600 | 0.98 | TSHR (0.59) | TSHRALDH1A1ADH1BADH1CADH1A | |
| SCHEMBL21554946 | 0.98 | TSHR (0.59) | TSHRALDH1A1ADH1BADH1CADH1A | |
| SCHEMBL616197 | 0.93 | — | — | |
| SCHEMBL10574954 | 0.91 | TSHR (0.62) | TSHRALDH1A1ADH1BADH1CADH1A | |
| Hydrochloric Acid SCHEMBL22771565 | 0.91 | TSHR (0.52) | TSHRALDH1A1ADH1BADH1CADH1A | |
| SCHEMBL8033193 | 0.91 | TSHR (0.68) | TSHRALDH1A1ADH1BADH1CADH1A | |
| Hydrochloric Acid SCHEMBL23277190 | 0.88 | TSHR (0.59) | TSHRALDH1A1ADH1BADH1CADH1A | |
| SCHEMBL22753257 | 0.88 | TSHR (0.73) | TSHRALDH1A1ADH1BADH1CADH1A | |
| SCHEMBL22756213 | 0.88 | TSHR (0.46) | TSHRALDH1A1ADH1BADH1CADH1A | |
| SCHEMBL9214189 | 0.88 | TSHR (0.73) | TSHRALDH1A1ADH1BADH1CADH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190133622-A1 | ANTI-JAMMING AND MACERATING THROMBECTOMY APPARATUSES AND METHODS | STRYKER CORPORATION (US) | 2019-05-09 | — | — | US | disclosed |
| US-8084596-B2 | Regulated apoptosis | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110003385-A1 | REGULATED TRANSCRIPTION OF TARGETED GENES AND OTHER BIOLOGICAL EVENTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2011-01-06 | — | — | US | disclosed |
| US-20100323420-A1 | REGULATED APOPTOSIS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2010-12-23 | — | — | US | disclosed |
| EP-0804561-B1 | REGULATED TRANSCRIPTION OF TARGETED GENES AND OTHER BIOLOGICAL EVENTS | UNIV LELAND STANFORD JUNIOR (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20090060888-A1 | Regulated transcription of targeted genes and other biological events | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-03-05 | — | — | US | disclosed |
| EP-1978095-A1 | Chimeric receptor proteins for controlling signal transduction and ligands binding thereto | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2008-10-08 | — | — | EP | disclosed |
| US-7084154-B2 | 2-(aminomethyl) arylamide analgesics | PHARMACOPEIA DRUG DISCLOVERY, INC. (US) | 2006-08-01 | — | — | US | disclosed |
| US-20060078969-A1 | Regulated transcription of targeted genes and other biological events | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2006-04-13 | — | — | US | disclosed |
| US-20060035325-A1 | Regulated apoptosis | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2006-02-16 | — | — | US | disclosed |
| US-5869337-A | OLIGOMERIZES TWO OR MORE CHIMERIC PROTEIN MOLECULES TO FORM A LIGAND CROSS-LINKED PROTEIN COMPLEX | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1999-02-09 | — | — | US | disclosed |
| US-5834266-A | A GENETIC CONSTRUCT ENCODING A CHIMERIC PROTEIN HAVING AN ACTIVATABLE APOPTOSIS-DOMAIN TO COMPLEX WITH A NONPROTEIN, MEMBRANE-PERMEABLE LIGAND WHICH THEN BINDS TO ANOTHER PROTEIN THEREBY ACTIVATING THE APOPTOSIS-INDUCING DOMAIN | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 1998-11-10 | — | — | US | disclosed |
| US-5830462-A | DIMERIZATION, OLIGOMERIZATION OF PROTEINS; ACTIVATION OF CELLMEMBRANE RECEPTORS | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 1998-11-03 | — | — | US | disclosed |
| EP-0776359-A4 | REGULATED APOPTOSIS | UNIV LELAND STANFORD JUNIOR (US) | 1998-09-09 | — | — | EP | disclosed |
| EP-0804561-A1 | REGULATED TRANSCRIPTION OF TARGETED GENES AND OTHER BIOLOGICAL EVENTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1997-11-05 | — | — | EP | disclosed |
| EP-0776335-A1 | REGULATABLE ELIMINATION OF GENE EXPRESSION, GENE PRODUCT FUNCTION AND ENGINEERED HOST CELLS | ARIAD GENE THERAPEUTICS, INC. (US) | 1997-06-04 | — | — | EP | disclosed |
| EP-0776359-A1 | REGULATED APOPTOSIS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1997-06-04 | — | — | EP | disclosed |
| WO-1996006111-A1 | REGULATABLE ELIMINATION OF GENE EXPRESSION, GENE PRODUCT FUNCTION AND ENGINEERED HOST CELLS | ARIAD GENE THERAPEUTICS, INC. (US) | 1996-02-29 | — | — | WO | disclosed |
| WO-1995002684-A1 | REGULATED APOPTOSIS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1995-01-26 | — | — | WO | disclosed |
| WO-1994018317-A1 | REGULATED TRANSCRIPTION OF TARGETED GENES AND OTHER BIOLOGICAL EVENTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1994-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090060888-A1 | Regulated transcription of targeted genes and other biological events | NFATC1, CD4, ACIN1 | TSHR 329/4885ALDH1A1 4860/4885ADH1B 4401/4885 |
| US-20060035325-A1 | Regulated apoptosis | BAX, CCAR2, DDIT3 | TSHR 3564/4885ALDH1A1 4468/4885ADH1B 3546/4885 |
| US-20060078969-A1 | Regulated transcription of targeted genes and other biological events | DGKZ, BID, TARBP1 | TSHR 225/4885ALDH1A1 4862/4885ADH1B 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.